Key facts
- It has raised $19.0M across 1 recorded rounds; the latest was Early Stage VC ($14.0M) in Dec 2024.
- Notable investors include The Milder Community Property Trust.
- Durvena has filed 1 Form D with the SEC, most recently Jan 2025 ($14.0M sold to 37 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Durvena
Funding rounds
1 roundsAbout Durvena
Developer of a tissue treatment technology designed for treating vein grafts for long-term patency. The company's technology commercializes photochemical tissue passivation that strengthens venous tissue and reduces the potential for graft failure and associated complications like clotting or restenosis, enabling healthcare providers with improved surgical outcomes and ensuring better long-term results for patients.
- Sector
- Healthcare
- HQ
- Overland Park, KS, United States
- Founded
- 2019
- Employees
- 4
- Website
- durvena.com/
- Ownership
- Privately Held (backing)
Durvena doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Durvena shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Durvena in its N-PORT filings yet. We sweep new filings monthly.